Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: A randomized, double-blind, placebo-controlled trial

Supportive Care in Cancer

Volumn 22, Issue 5, 2014, Pages 1223-1231

  Guo, Ying ^a   Jones, Desiree ^a   Palmer, J Lynn ^a   Forman, Arthur ^a   Dakhil, Shaker R ^b   Velasco, Maria R ^c   Weiss, Matthias ^d   Gilman, Paul ^e   Mills, G M ^f   Noga, Stephen J ^g   Eng, Cathy ^a   Overman, Michael J ^a   Fisch, Michael J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Cancer Center of Kansas   (United States)

^c Cancer Care Specialists   (United States)

^d MARSHFIELD CLINIC   (United States)

^e Main Line Clinical Laboratories   (United States)

^f LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^g Alvin and Lois Lapidus Cancer Institute   (United States)

Author keywords

Alpha lipoic acid; Chemotherapy induced peripheral neuropathy; Neuropathy; Oxaliplatin; Sensory neuropathy toxicity

Indexed keywords

CISPLATIN; OXALIPLATIN; PLACEBO; THIOCTIC ACID;

ADULT; ANEMIA; ARTICLE; BRIEF PAIN INVENTORY; CANCER PATIENT; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY GYNECOLOGIC ONCOLOGY GROUP NEUROTOXICITY; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NCI COMMON TOXICITY CRITERIA FOR ADVERSE; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; PLACEBOS; THIOCTIC ACID;

EID: 84897559344     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-2075-1     Document Type: Article

References (39)

1. Tofthagen C (2010) Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 14(3):E22-E28. doi:10.1188/10.CJON.E22-E28
2. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33(1):15-49. doi:10.1053/j.seminoncol.2005.12.010 (Pubitemid 43214485)
3. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63(15):1549-1563 (Pubitemid 36976138)
4. Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC (2008) Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15(29):3081-3094
5. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC (2005) Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 32(1):51-60. doi:10.1002/mus.20340 (Pubitemid 40917889)
6. Uwah AN, Ackler J, Leighton JC, Pomerantz S, Tester W (2012) The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Clin Colorectal Cancer 11(4):275-279. doi:10.1016/j.clcc.2012.05.002
7. Argyriou AA, Polychronopoulos P, Koutras A, Xiros N, Petsas T, Argyriou K, Kalofonos HP, Chroni E (2007) Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy. Eur J Cancer Care (Engl) 16(3):231-237. doi:10.1111/j.1365-2354.2006.00718.x
8. Cersosimo RJ (1989) Cisplatin neurotoxicity. Cancer Treat Rev 16(4):195-211
9. Extra JM, Marty M, Brienza S, Misset JL (1998) Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25(2 Suppl 5):13-22 (Pubitemid 28248697)
10. Eng C (2009) Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol 6(4):207-218. doi:10.1038/nrclinonc.2009.16
11. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938-2947 (Pubitemid 30644117)
12. Tofthagen C, McAllister RD, McMillan SC (2011) Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clinical journal of oncology nursing 15(2):182-188. doi:10.1188/11.cjon.182-188
13. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 31(21):2699-2707. doi:10.1200/jco.2013.49.1514
14. Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD, Colman LK, Lanier KS, Pajon ER, Cella D, Smith RE, O'Connell MJ, Costantino JP, Wolmark N (2007) Neurotoxicity fromoxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25(16):2205-2211. doi:10.1200/JCO.2006.08.6652 (Pubitemid 46954644)
15. Pietrangeli A, Leandri M, Terzoli E, Jandolo B, Garufi C (2006) Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 56(1):13-16. doi:10.1159/000094376 (Pubitemid 44359537)
16. Schloss JM, Colosimo M, Airey C, Masci PP, Linnane AW, Vitetta L (2013) Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review. Clin Nutr 32(6):888-893. doi:10.1016/j.clnu.2013.04.007
17. Kopec JA, Land SR, Cecchini R, Ganz P, Cella D, Costantino J, Wieand HS, Smith RE, Kuebler JP, Wolmark N (2006) Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. J Support Oncol 4(8):W1-W7
18. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44(11):1507-1515. doi:10.1016/j.ejca.2008.04.018
19. Albers JW, Chaudhry V, Cavaletti G, Donehower RC (2011) Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2, CD005228. doi:10.1002/14651858.CD005228.pub3
20. Ibrahimpasic K (2013) Alpha lipoic acid and glycaemic control in diabetic neuropathies at type 2 diabetes treatment. Med Arh 67(1):7-9
21. Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M (2013) Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract. doi:10.1111/papr.12054
22. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L (1984) Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34(7):934-938 (Pubitemid 14076460)
23. Evans P, Halliwell B (1999) Free radicals and hearing. Cause, consequence, and criteria. Ann N Y Acad Sci 884:19-40
24. Gedlicka C, Scheithauer W, Schull B, Kornek GV (2002) Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 20(15):3359-3361 (Pubitemid 34831539)
25. Ruhnau KJ, Meissner HP, Finn JR, Reljanovic M, Lobisch M, Schutte K, Nehrdich D, Tritschler HJ, Mehnert H, Ziegler D (1999) Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabetic medicine : a journal of the British Diabetic Association 16(12):1040-1043
26. Ziegler D, Reljanovic M, Mehnert H, Gries FA (1999) Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association 107(7):421-430. doi:10.1055/s-0029-1212132
27. Huang HQ, Brady MF, Cella D, Fleming G (2007) Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 17(2):387-393. doi:10.1111/j.1525-1438.2007.00794 (Pubitemid 46426765)
28. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA (2003) Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane). Cancer 98(4):822-831. doi:10.1002/cncr. 11578 (Pubitemid 36959280)
29. Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, Cella D (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13(6):741-748 (Pubitemid 38235217)
30. Cella D (1997) FACIT manual: manual of the functional assessment of chronic illness therapy (FACIT) measurement system. Center on Outcomes, Research and Education
31. (CDC) CfDCaP (2011) Cancer survivors-United States, 2007. MMWR Morb Mortal Wkly Rep 60 (9):269-272
32. Simmonds MJ (2002) Physical function in patients with cancer: psychometric characteristics and clinical usefulness of a physical performance test battery. J Pain Symptom Manage 24(4):404-414
33. Cleeland C (1991) Research in cancer pain. What we know and what we need to know. Cancer 67(3 Suppl):823-827
34. Atkinson TM, Mendoza TR, Sit L, Passik S, Scher HI, Cleeland C, Basch E (2010) The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations. Pain medicine (Malden, Mass) 11(3):337-346. doi:10.1111/j.1526-4637.2009.00774.x
35. Program CTE (2006) Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ docs/ctcaev3.pdf. Accessed 1 Oct 2013
36. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353(5):487-497. doi:10.1056/NEJMra050100 (Pubitemid 41127293)
37. Haynes RB, McDonald HP, Garg AX (2002) Helping patients follow prescribed treatment: clinical applications. JAMA 288(22):2880-2883 (Pubitemid 35425074)
38. Waterhouse DM, Calzone KA, Mele C, Brenner DE (1993) Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11(6):1189-1197 (Pubitemid 23163362)
39. Joseph EK, Chen X, Bogen O, Levine JD (2008) Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain 9(5):463-472. doi:10.1016/j.jpain.2008.01.335